ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Arthur Przybyl sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $61.83, for a total transaction of $2,473,200.00. Following the completion of the sale, the insider now directly owns 225,706 shares of the company’s stock, valued at $13,955,401.98. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of ANIP stock traded down $2.51 during trading hours on Friday, reaching $57.06. 54,238 shares of the stock traded hands, compared to its average volume of 99,043. ANI Pharmaceuticals, Inc. has a 1-year low of $42.23 and a 1-year high of $74.70. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.36 and a quick ratio of 2.39. The firm has a market capitalization of $665.38, a P/E ratio of 15.81 and a beta of 2.91.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.06. The firm had revenue of $47.30 million for the quarter, compared to analyst estimates of $52.55 million. ANI Pharmaceuticals had a negative net margin of 0.61% and a positive return on equity of 23.41%. The company’s revenue for the quarter was up 23.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.84 EPS. sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 5.17 EPS for the current fiscal year.
A number of brokerages have recently weighed in on ANIP. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Canaccord Genuity set a $75.00 target price on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, December 9th. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. ValuEngine lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. Finally, TheStreet lowered shares of ANI Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $72.25.
A number of hedge funds have recently bought and sold shares of ANIP. Northern Trust Corp grew its position in ANI Pharmaceuticals by 5.2% in the second quarter. Northern Trust Corp now owns 112,905 shares of the specialty pharmaceutical company’s stock worth $5,285,000 after acquiring an additional 5,599 shares in the last quarter. Vanguard Group Inc. grew its position in ANI Pharmaceuticals by 8.1% in the second quarter. Vanguard Group Inc. now owns 476,948 shares of the specialty pharmaceutical company’s stock worth $22,322,000 after acquiring an additional 35,722 shares in the last quarter. Parametric Portfolio Associates LLC grew its position in ANI Pharmaceuticals by 26.9% in the second quarter. Parametric Portfolio Associates LLC now owns 15,020 shares of the specialty pharmaceutical company’s stock worth $703,000 after acquiring an additional 3,183 shares in the last quarter. Crossmark Global Holdings Inc. bought a new stake in ANI Pharmaceuticals in the third quarter worth approximately $226,000. Finally, Chicago Equity Partners LLC grew its position in ANI Pharmaceuticals by 13.8% in the third quarter. Chicago Equity Partners LLC now owns 22,570 shares of the specialty pharmaceutical company’s stock worth $1,185,000 after acquiring an additional 2,745 shares in the last quarter. 56.06% of the stock is owned by institutional investors.
WARNING: “Insider Selling: ANI Pharmaceuticals, Inc. (ANIP) Insider Sells 40,000 Shares of Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/insider-selling-ani-pharmaceuticals-inc-anip-insider-sells-2473200-00-in-stock.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.